CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
Are you looking for an excellent opportunity to expand your research experience and to complement your clinical and scientific training?
Team up with a strong partner to support your translational research ambitions! Strengthen your profile throug...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential...
